Clinical course of atypical parathyroid neoplasm with soft tissue extension

Author:

Feldman Hope A.1,Busaidy Naifa L.2,Tame‐Elorduy Andres3,Silva Angelica Kika4,Halfteck Gili3,Merriman Kelly5,Waguespack Steven G.2,Graham Paul H.3,Williams Michelle D.6,Perrier Nancy D.3

Affiliation:

1. Department of General Surgery Geisinger Medical Center Danville Virginia USA

2. Department of Endocrine Neoplasia and Hormonal Disorders The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

4. Department of Head and Neck Surgery Universidad Finis Terrae Santiago Chile

5. Department of Protocol Research The University of Texas MD Anderson Cancer Center Houston Texas USA

6. Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center Houston Texas USA

Abstract

AbstractBackground and ObjectivesThe American Joint Committee on Cancer (AJCC) TNM staging system defines atypical parathyroid neoplasia (APN) as tumor in situ (Tis) and reserves the definition of parathyroid carcinoma (PC) to parathyroid tumor with invasion into surrounding structures. Because the parathyroid gland has no true capsule, “extension” with APN versus microscopic “invasion” of surrounding soft tissue can be difficult and confusing for clinicians. We aimed to determine the clinical course of atypical parathyroid neoplasm with and without soft tissue extension and parathyroid carcinoma with only soft tissue invasion (pT1) and to report the outcomes.MethodsFollowing an IRB‐approved protocol, we identified all patients treated for parathyroid neoplasm or cancer at our single tertiary care cancer center from 1990 to 2021. We excluded all patients with evidence of clinical or pathologic gross invasion into surrounding structures (pT2 or higher), lymph node involvement, or metastatic disease. By definition, this excluded all cases where the distinction was clinically evident to the surgeon at the time of the operation based on finding a hard, firm, sticky, or discolored parathyroid gland. Only patients with pathologic T1 (pT1) parathyroid carcinoma or APN were included. All pathologic examinations were independently re‐reviewed by a single designated expert senior endocrine pathologist. The definition of APN strictly followed the WHO definition of a clinically worrisome lesion having features including fibrous bands or increased mitotic rate, necrosis, or trabecular growth that did not meet robust criteria for frank invasion. Pathologic T1 disease was defined as invasion limited to soft tissue. Analyses were performed using R version 4.0.2 and Jamovi.ResultsOf all PC patients at our institution, only 71 met the strict inclusion criteria of APN or pT1. Forty‐four patients had pT1 disease and 27 had APN: 12 of the APN had soft tissue extension, and 15 had no soft tissue extension. The groups were similar with regard to age at diagnosis (p = 0.328). The average follow‐up duration was 84 months from initial surgical intervention. Of the 12 with APN, one patient (1/12; 8%) with soft tissue extension recurred, developed distant metastases, and subsequently died during follow up. Of the 44 patients with pT1 PC, six developed distant metastases and 13 (13/44; 30%) died during the follow‐up period. One patient with APN and soft tissue extension recurred and died and no patient with APN and no soft tissue extension died.ConclusionsPatients with APN and extension into soft tissue have a clinical course similar to that of APN without soft tissue extension. APN with soft tissue extension is a different disease from pT1 disease with invasion of soft tissue. The pTis classification appears justified for APN with and without soft tissue extension.

Publisher

Wiley

Reference13 articles.

1. Contemporary evaluation and management of parathyroid carcinoma;Fingeret AL;JCO Oncol Pract,2021

2. Pathology data set for reporting parathyroid carcinoma and atypical parathyroid neoplasm: recommendations from the international collaboration on cancer reporting;Williams MD;Hum Pathol,2021

3. Parathyroid carcinoma;Cetani F;Front Horm Res,2019

4. Overview of the 2022 WHO classification of parathyroid tumors;Erickson LA;Endocr Pathol,2022

5. LandryC WangT AsareE et al. Parathyroid. In: Amin M ed.AJCC Cancer Staging Manual. 8th ed. Springer International Publishing;2017:903.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3